Supplementary Table 2.  Clinical characteristics of the metastatic patients with central nervous system (CNS) involvement included in the study at the time of sample collection
		Lung   cancer  (n=13)		Breast   cancer  (n=14)		Kidney   cancer  (n=4)		Melanoma (n=11)
TNM stage at disease diagnosis		n	%		n	%		n	%		n	%
I/ II		0	0		6	43		1	25		2	18
III		2	15		3	21		0	0		4	36
IV*		11	85		5	36		3	75		5	46
Histological   subtype  ( lung   cancer )												
Non- small   cell		13	100		_	_		_	_		_	_
Small  cell		0	0		_	_		_	_		_	_
IMDC score ( kidney   cancer )												
Good prognosis		_	_		_	_		1	25		_	_
Intermediate  prognosis		_	_		_	_		0	0		_	_
Bad  prognosis		_	_		_	_		3	75		_	_
Clinically   relevant  molecular  alterations												
EGFR  alterations  ( lung   cancer )		0	0		_	_		_	_		_	_
ALK  alterations  ( lung   cancer )		1	7		_	_		_	_		_	_
No  alterations  ( lung   cancer )		12	93		_	_		_	_		_	_
Luminal  phenotype  ( breast   cancer )		_	_		3	21		_	_		_	_
HER2 +   phenotype  ( breast   cancer )		_	_		8	58		_	_		_	_
Triple negative phenotype (breast cancer)		_	_		3	21		_	_		_	_
BRAF  alterations  (melanoma)		_	_		_	_		_	_		6	54
No  alterations  (melanoma)		_	_		_	_		_	_		5	46
Number of previous systemic therapies received for metastatic disease												
0		8	62		0	0		2	50		8	73
1  or  more		5	38		14	100		2	50		3	27
Type of systemic therapies received for metastatic disease												
Chemotherapy		4	31		13	93		_	_		0	0
Immune   checkpoint   inhibitors		2	15		2	14		1	25		2	18
Targeted therapy (including hormone therapy)		0	0		12	86		3	75		2	18
No  systemic   treatment		8	62		0	0		2	50		8	73
Type of tumor progression at the time of sample collection												
CNS without progression in other locations		7	54		5	36		1	25		2	18
CNS with progression in other locations		6	46		9	64		3	75		9	82
Location of metastatic disease at the time of sample collection												
CNS  only		3	22		0	0		0	0		0	0
CNS  with   bone /serosa		0	0		0	0		0	0		0	0
CNS  with   viscera		5	39		5	36		1	25		9	82
CNS with bone/serosa and viscera		5	39		9	64		3	75		2	18
Characteristics of recent CNS involvement												
New single  lesion		5	39		2	14		2	50		3	27
2  or  more  lesions		7	54		10	72		2	50		8	73
Other  ( leptomeningeal  carcinomatosis)		1	7		2	14		0	0		0	0